All In Biotech

Drug Trial Radar · NCT06953726

Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

CSP #2037T - Veterans Affairs Learning Health System Initiative to Assess Novel Screening vs. Usual Care and Treatment With Apixaban vs. Rivaroxaban in Veterans With Atrial Fibrillation (VALIANT-AF-T) Trial

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 10,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

10,000

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Oct 4, 2032

Study completion Oct 3, 2033

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
Collaborators
Food and Drug Administration (FDA)
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They are considered by many doctors to have similar benefits and risks, but no one knows for sure. * The trial only enrolls patients with a diagnosis of atrial fibrillation ("A Fib") or atrial flutter. Most participants will be age 65 or older, and should already be taking apixaban or rivaroxaban. * The investigators will measure, in about 10,000 VA patients nationally, whether the rates of stroke, major bleeding, or death differ between these two drugs. * The trial will last about 7 years, but after the first prescription, all information will be collected from electronic medical records.

Conditions

  • Atrial Fibrillation

Interventions

  • ApixabanDrug

    Study participants will be randomized to twice daily oral administration of apixaban 5 milligrams (mg). Reduced dose apixaban (2.5 mg twice daily) will be given to participants who meet 2 of the 3 criteria: age 80 years, body weight 60 kg, and serum creatinine 1.5 mg/dL.

  • RivaroxabanDrug

    Study participants will be randomized to daily oral administration of rivaroxaban 20 milligrams (mg). Reduced dose rivaroxaban (15 mg once daily) will be given to participants with a creatinine clearance 15-50 mL/min.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Onset of ISTH Major Bleeding EventTime frame: 3 years
  2. Time to First StrokeTime frame: 3 years
  3. Time to First Systemic EmbolismTime frame: 3 years
  4. Time to All-Cause MortalityTime frame: 3 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • VA Greater Los Angeles Healthcare System, West Los Angeles, CA

    West Los Angeles, California · Active not recruiting

  • Miami VA Healthcare System, Miami, FL

    Miami, Florida · Recruiting

  • Boston VA CSP Coordinating Center

    Boston, Massachusetts · Recruiting

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

    Boston, Massachusetts · Not yet recruiting

  • Minneapolis VA Call Center

    Minneapolis, Minnesota · Recruiting

  • Louis Stokes VA Medical Center, Cleveland, OH

    Cleveland, Ohio · Active not recruiting

  • VA Portland Health Care System, Portland, OR

    Portland, Oregon · Recruiting

  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Philadelphia, Pennsylvania · Active not recruiting

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.